Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Characterization of the PKPD relationship of reduced cholesterolemia by the peptide PCSK9-LDL receptor protein-protein interaction inhibitor P7 in mice and non-human primates

  • In: Poster Presentation
  • At: Stockholm (Sweden) (2017)
  • Type: Poster
  • Poster code: P-A-067-Monday
  • By: BUETERS, Tjerk (Merck & Co, Inc, PPDM, Westpoint, United States)
  • Co-author(s): Tjerk Bueters: PPDM, Merck & Co, Inc, Westpoint, PA, United States
    Kenneth Koeplinger: PPDM, Merck & Co, Inc, Westpoint, PA, United States
    Philippe Costet: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
    Beth Murphy: Department of In Vivo Pharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
    Scott Salowe: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
    Hratch Zokian: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
    Michael Kavana: Department of In VitroPharmacology, Merck & Co, Inc, Kenilworth, NJ, United States
    Candice Alleyne: Department of Discovery Pharmaceutical Sciences, Merck & Co, Inc, Kenilworth, NJ, United States
    Annette Bak: Department of Discovery Pharmaceutical Sciences, Merck & Co, Inc, Kenilworth, NJ, United States
    Sheng-Ping Wang: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
    Yongcheng Huang: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
    Angela Kerekes: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
    James Tata: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
    Yusheng Xiong: Discovery Chemistry, Merck & Co, Inc, Kenilworth, NJ, United States
    Shirly Pinto: Department of Cardiometabolic Diseases, Merck & Co, Inc, Kenilworth, NJ, United States
  • Abstract:

    Backgrounds

    PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a clinically and genetically validated target to effectively reduce elevated LDL-c levels. Anti-PCSK9 antibody therapies (Repatha/Amgen, Praluent/Sanofi-Regeneron) have recently been approved as adjunct to diet and maximally tolerated statin therapy for patients suffering from..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses